Complex alternative splicing of the Smarca2 gene suggests the importance of Smarca2-B variants

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 386-400

  Yang, Min ^a,d   Sun, Yuan ^a   Ma, Ling ^b   Wang, Chenguang ^c   Wu, Jian Min ^b   Bi, Anding ^a   Liao, D Joshua ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b GUANGXI VETERINARY RESEARCH INSTITUTE   (China)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Alternative splicing; BRM; Cancer; Cyclin D1; Smarca2; SWI SNF complex; Tumor suppressor gene

Indexed keywords

BRM PROTEIN; CYCLIN D1; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; EXON; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INTRON; MOUSE; NONHUMAN; RNA SPLICING; SMARCA2 A GENE; SMARCA2 B GENE;

EID: 84865120235     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.386     Document Type: Article

References (39)

1. Stamm S, Ben-Ari S, Rafalska I et al. Function of alternative splicing. Gene 2005;344:1-20.
2. Johnson JM, Castle J, Garrett-Engele P et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003;302:2141-4.
3. Kim E, Goren A, Ast G. Alternative splicing and disease. RNA Biol 2008;5:17-9.
4. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008;24:7-10.
5. Pensabene M, Spagnoletti I, Capuano I et al. Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol 2009;20:874-8.
6. Park JW, Graveley BR. Complex alternative splicing. Adv Exp Med Biol 2007;623:50-63.
7. Guo W, Bharmal SJ, Esbona K, Greaser ML. Titin diversity-alternative splicing gone wild. J Biomed Biotechnol 2010;2010:753675.
8. Shen H, Powers N, Saini N et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res 2008;68:10154-62.
9. Trouche D, Le CC, Muchardt C, Yaniv M, Kouzarides T. RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci U S A 1997;94:11268-73.
10. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009;28:1653-68.
11. Ito T, Watanabe H, Yamamichi N et al. Brm transactivates the telomerase reverse transcriptase (TERT) gene and modulates the splicing patterns of its transcripts in concert with p54 nrb. Biochem J 2007;411:201-9.
12. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, Weissman BE. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 2001;186:136-45.
13. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63:560-6.
14. Yamamichi N, Inada K, Ichinose M et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 2007;67:10727-35.
15. Rosson GB, Bartlett C, Reed W, Weissman BE. BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton. J Cell Physiol 2005;205:286-94.
16. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: impli-cations for clinical targeted therapy. Oncogene 2007;26:7058-66.
17. Gunduz E, Gunduz M, Ali MA et al. Loss of heterozygosity at the 9p21-24 region and identification of BRM as a candidate tumor suppressor gene in head and neck squamous cell carcinoma. Cancer Invest 2009;27:661-8.
18. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000;2:331-4.
19. Wang Y, Thakur A, Sun Y et al. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Cancer Res 2007;67:3698-707.
20. Biliran H Jr., Wang Y, Banerjee S et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005;11:6075-86.
21. Biliran H Jr., Banerjee S, Thakur A et al. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells. Clin Cancer Res 2007;13:2811-21.
22. Shen KC, Miller F, Tait L et al. Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses. Breast Cancer Res Treat 2006;98:357-64.
23. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994;91:709-13.
24. Durnam DM, Palmiter RD. A practical approach for quantitating specific mRNAs by solution hybridization. Anal Biochem 1983;131:385-93.
25. Wang Y, Thakur A, Sun Y et al. Synergistic effect of cyclin D1 and c-Myc leads to more aggressive and invasive mammary tumors in severe combined immunodeficient mice. Cancer Res 2007;67:3698-707.
26. Yamamichi N, Yamamichi-Nishina M, Mizutani T et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 2005;24:5471-81.
27. Yamamichi-Nishina M, Ito T, Mizutani T, Yamamichi N, Watanabe H, Iba H. SW13 cells can transition between two distinct subtypes by switching expression of BRG1 and Brm genes at the post-transcriptional level. J Biol Chem 2003;278:7422-30.
28. Tyagi A, Ryme J, Brodin D, Ostlund Farrants AK, Visa N. SWI/SNF associates with nascent pre-mRNPs and regulates alternative pre-mRNA processing. PLoS Genet 2009;5:e1000470.
29. Van Der KK, Beyaert R, Inze D, De VL. Translational control of eukaryotic gene expression. Crit Rev Biochem Mol Biol 2009;44:143-68.
30. Iacono M, Mignone F, Pesole G. uAUG and uORFs in human and rodent 5'untranslated mRNAs. Gene 2005;349:97-105.
31. Ivanov IP, Atkins JF, Michael AJ. A profusion of upstream open reading frame mechanisms in polyamine-responsive translational regulation. Nucleic Acids Res 2010;38:353-9.
32. King HA, Cobbold LC, Willis AE. The role of IRES trans-acting factors in regulating translation initiation. Biochem Soc Trans 2010;38:1581-6.
33. Spriggs KA, Stoneley M, Bushell M, Willis AE. Re-programming of translation following cell stress allows IRES-mediated translation to predominate. Biol Cell 2008;100:27-38.
34. Stoneley M, Subkhankulova T, Le Quesne JP et al. Analysis of the c-myc IRES; a potential role for cell-type specific trans-acting factors and the nuclear compartment. Nucleic Acids Res 2000;28:687-94.
35. Nyiko T, Sonkoly B, Merai Z, Benkovics AH, Silhavy D. Plant upstream ORFs can trigger nonsense-mediated mRNA decay in a size-dependent manner. Plant Mol Biol 2009;71:367-78.
36. Wang C, Tai Y, Lisanti MP, Liao DJ. c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther 2011;11:615-26.
37. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011;10:57-67.
38. Chen G, Wang J, Liu Z, Kornmann M. Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1. Pancreas 2008;37:159-64.
39. Olshavsky NA, Comstock CE, Schiewer MJ et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res 2010;70:3975-84.